Literature DB >> 2758560

Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

E Institóris1, K Szikla, L Otvös, F Gál.   

Abstract

Dianhydrogalactitol (DAG) increased the life span of both BCNU-sensitive and -resistant L1210 tumor-bearing mice. However, the BCNU-resistant strain showed slightly lower sensitivity against DAG, which could be overcome by an increase in drug dose of ca. 20%. The somewhat lower sensitivity was proportional to a slightly reduced DNA cross-linking formation induced by DAG in BCNU-resistant cells. The amount of DNA cross-links was determined by measurement of the 1,6-di(guaninyl)-galactitol content of DNA. The slight reduction in cross-links is not attributable to DNA repair but rather to other factors that seem to prevent the formation of DNA-drug adducts. The absence of cross-resistance is explained by different kinds of DNA damage caused by the two alkylating agents and the presumably different defense mechanisms developed by cells against these lesions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758560     DOI: 10.1007/BF00304764

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  NITROGEN MUSTARD-RESISTANT YOSHIDA SARCOMA AND CROSS-RESISTANCE STUDIES.

Authors:  V UJHAZY; A WINKLER
Journal:  Neoplasma       Date:  1965       Impact factor: 2.575

2.  Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.

Authors:  D L Ahmann; M J O'Connell; H F Bisel; J H Edmonson; R G Hahn; S Frytak
Journal:  Cancer Treat Rep       Date:  1977 Jan-Feb

3.  Investigations on the mechanism of action of cytotoxic hexitols. I. Cross-resistance investigations on Yoshida sarcoma tumour.

Authors:  A Jeney; J Szabó; T Vályi-Nagy
Journal:  Neoplasma       Date:  1968       Impact factor: 2.575

4.  Cross-linking of DNA induced by chloroethylnitrosourea is presented by O6-methylguanine-DNA methyltransferase.

Authors:  P Robins; A L Harris; I Goldsmith; T Lindahl
Journal:  Nucleic Acids Res       Date:  1983-11-25       Impact factor: 16.971

5.  Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.

Authors:  R T Eagan; R P Dinapoli; R C Hermann; R V Groover; D D Layton; M Scott
Journal:  Cancer Treat Rep       Date:  1982-08

6.  Development and some characteristics of a P388 leukemia strain resistant to 1, 2:5, 6-dianhydrogalactitol.

Authors:  J Bence; S Somfai-Relle; E Gáti
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

7.  In vivo study on alkylation site in DNA by the bifunctional dianhydrogalactitol.

Authors:  E Institoris
Journal:  Chem Biol Interact       Date:  1981-05       Impact factor: 5.192

Review 8.  Establishment of cross-resistance profiles for new agents.

Authors:  F M Schabel; H E Skipper; M W Trader; W R Laster; D P Griswold; T H Corbett
Journal:  Cancer Treat Rep       Date:  1983-10

9.  Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.

Authors:  R T Eagan; M M Ames; G Powis; J S Kovach
Journal:  Cancer Treat Rep       Date:  1982-02

10.  Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol(DBM)-resistant Yoshida S.C. sarcoma.

Authors:  E Csányi; M Halász
Journal:  Br J Cancer       Date:  1967-06       Impact factor: 7.640

View more
  3 in total

1.  Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.

Authors:  Beibei Zhai; Yue Li; Sudha Sravanti Kotapalli; Jeffrey Bacha; Dennis Brown; Anne Steinø; Mads Daugaard
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

2.  Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells.

Authors:  Shigeo Ohba; Kei Yamashiro; Yuichi Hirose
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

3.  Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination.

Authors:  Beibei Zhai; Anne Steinø; Jeffrey Bacha; Dennis Brown; Mads Daugaard
Journal:  Cell Death Dis       Date:  2018-10-03       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.